Login to Your Account

Financings Roundup

Conatus Pharma Seeks $69M for Liver Drug Emricasan

By Marie Powers
Staff Writer

Friday, June 14, 2013

Conatus Pharmaceuticals Inc., which has quietly labored on liver drug emricasan (IDN-6556) since gaining global rights to the asset in its 2010 acquisition of Pfizer Inc. spin-out Idun Pharmaceuticals Inc., became the latest biotech to register with the SEC for an initial public offering (IPO). Filing its S-1 as an emerging growth company under the Jumpstart Our Business Startups Act of 2012, the San Diego-based firm is seeking to raise up to $69 million to continue the clinical development of emricasan, a pan-caspase inhibitor.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription